# CiLostAzol for pReventIon of Recurrent sTroke in Africa

Study · id `cardio:ct-nct06919835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06919835](<https://clinicaltrials.gov/study/NCT06919835>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06919835

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1100 participants.

## Technical summary

Registry record NCT06919835. Randomized; triple masking; primary purpose prevention. Start 2027-01-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1100 participants (planned count; ClinicalTrials.gov record NCT06919835, source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT06919835, source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2029-07-31 (anticipated) (ClinicalTrials.gov record NCT06919835, source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-08-31 (anticipated) (ClinicalTrials.gov record NCT06919835, source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)
- Countries: Ghana (ClinicalTrials.gov record NCT06919835, source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06919835-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: CiLostAzol for pReventIon of Recurrent sTroke in Africa
- Acronym: CLARITY-Africa
- Condition: Stroke
- Intervention (Drug): Cilostazol 100 mg
- Lead sponsor: Northern California Institute of Research and Education
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Northern California Institute of Research and Education (`cardio:org-northern-california-institute-of-research-and-education`)

## Provenance

Content hash: b40b677999cc7f88cce37156f67c50f8757e83cc6937128f22a2b24c43203dc2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
